MOTS-c Dosage: Protocols, Cycling, and Reconstitution

MOTS-c dosage is one of the least settled numbers in the peptide market, and the reason is simple. There is no published human dose finding study. Every figure quoted on a vendor page or a forum thread traces back either to rodent work measured in milligrams per kilogram, or to a convention that appeared early and then propagated because nobody had anything better to offer.

That does not make the numbers useless. It does mean they should be read as descriptions of what people run rather than as recommendations derived from evidence. This page sets out the ranges in circulation, the arithmetic that turns a vial into syringe units, the frequency and cycling logic, and the places where the reasoning is thinner than it looks.

The Dose Range That Actually Circulates

Across vendor protocol sheets, community write-ups and coaching templates, MOTS-c dosing converges on 5mg to 10mg per week in total. Within that band, three patterns account for almost everything you will encounter.

Notice that the weekly total barely moves across the three. The disagreement is about how to distribute it, not about how much to use, which is a useful signal in itself: when a market argues only about frequency, the underlying dose figure is usually an inherited convention rather than a measured optimum.

A standard vial is 10mg. At the conservative end, one vial is roughly a fortnight. At the standard end, it is a week. Cost per week is therefore the price of one vial or half of one, which is worth knowing before committing to a multi month block.

Where the Numbers Came From

The foundational MOTS-c work, principally from Pinchas Cohen's group, used mice. The mouse studies that produced the headline metabolic results dosed in the region of 5mg to 15mg per kilogram of body weight, typically by intraperitoneal injection, often daily. Scaled naively to an 80kg human that would be several hundred milligrams a day, which nobody does and nobody should.

Naive scaling is also wrong on its own terms. Interspecies dose translation normally uses body surface area rather than mass, which cuts the figure by roughly an order of magnitude, and even that is a rough correction for a signalling peptide whose target is intracellular. The honest summary is that the mouse doses do not translate into a human number with any confidence, and the 5mg to 10mg weekly convention was not derived from them. It was chosen because it was affordable, it was tolerable, and it produced subjective reports people liked.

Human MOTS-c research does exist, but it is observational rather than interventional. Circulating MOTS-c concentrations have been measured against exercise, ageing, insulin resistance and mitochondrial function. Those studies tell you the peptide is biologically meaningful. They do not tell you what an injected dose should be. The mechanism background is covered properly in the MOTS-c peptide guide, and the claimed effects are assessed against the evidence in MOTS-c benefits.

Reconstitution: Turning Milligrams Into Syringe Units

This is where most dosing errors happen, and they are arithmetic errors rather than judgement errors. A standard U-100 insulin syringe reads 100 units to 1mL. The unit marking measures volume, not peptide, so the same 25 unit draw delivers a completely different dose depending on how much water went into the vial.

For a 10mg vial:

Two millilitres is the sensible default. It puts every common dose on a whole or half unit marking that can be read without squinting, and it keeps the injection volume small enough to be comfortable subcutaneously. One millilitre concentrates the vial to the point where a small misread becomes a large dose error, and three millilitres wastes syringe capacity for no benefit.

The mechanics of getting there, the slow stream down the vial wall, the swirl rather than shake, the vented equalisation, are the same for MOTS-c as for anything else and are covered in the reconstitution guide. The diluent question is covered in the bacteriostatic water guide, and the short version is that bacteriostatic water rather than sterile water is what makes a multi dose vial defensible over two weeks.

Frequency: Three Times Weekly Against Daily

The case for three times weekly rests on how MOTS-c is thought to work. It is not a receptor agonist maintaining an effect while it occupies a binding site. It acts as a mitochondrial derived signalling peptide that influences AMPK activity and, through it, transcriptional programmes including the stress response regulator ATF4. Those are changes in cellular state that persist well beyond the peptide's presence in plasma, which is short.

If the effect is a triggered programme rather than a maintained occupancy, spacing doses is reasonable and daily dosing buys little. Monday, Wednesday, Friday is the pattern most protocols land on, and it has the practical advantage of being easy to keep to.

The case for daily splitting is weaker but not empty. Smaller individual doses may reduce injection site irritation, and some people report a smoother subjective energy profile. Neither claim has a study behind it. What is certain is that daily dosing triples the number of injections for the same weekly milligram total, and for a compound running for six weeks that is a real adherence cost. The injection guide covers site rotation, which matters more once you are injecting five or more times a week.

Cycle Length and Why Blocks Exist

Four to eight weeks on, followed by a comparable break, is the standard shape. Unlike the dose figure, this one has at least a coherent rationale behind it even if it has no data.

MOTS-c appears to act as an energy stress signal, something the cell produces when mitochondrial conditions call for an adaptive response. Compounds that work by mimicking a stress signal are the ones where continuous administration is most plausibly counterproductive, because the adaptive value of a signal depends partly on it being intermittent. Exercise follows the same logic. Nobody argues that training without recovery days produces better adaptation.

That is reasoning by analogy, not evidence, and it should be labelled as such. What can be said with more confidence is that there is no long term human exposure data for injected MOTS-c at all, so an indefinite protocol is running an experiment with no comparison group. A defined block with a defined end is the more conservative structure, and it also gives you a clean window to judge whether anything actually changed. The before and after page covers what the timeline typically looks like and how much of it survives scrutiny.

Timing Around Training

The convention is to inject thirty to sixty minutes before a training session on dosing days. The logic is that exercise activates AMPK and MOTS-c is thought to act on the same node, so the two might compound.

It is a defensible guess. It is also unvalidated in humans, and the downstream effects being invoked are transcriptional, unfolding across hours and days rather than within a pre workout window. If injecting before training makes a protocol easier to remember, it costs nothing. If it means skipping doses on rest days and drifting below the intended weekly total, the timing convention has done more harm than good. Non training days are fine for dosing, and consistency beats precision here by a wide margin.

Dose Adjustment, Tolerance and Who Runs Lower

Body weight scaling is applied inconsistently in practice and the evidence does not settle it. Given that the base figure is a convention rather than a measured optimum, precision scaling of an imprecise number is false rigour. A practical compromise is to start at the lower end regardless of body weight, run two to three weeks, and only consider moving up if nothing at all has changed. That is also the sensible approach for anyone new to injectable peptides or running MOTS-c alongside other metabolically active compounds. The side effects page covers what actually gets reported, which is mostly local and mild, along with the athletic testing question that matters for anyone competing under WADA rules.

Going above roughly 10mg a week is where the reasoning gets thin. There is no dose response curve to point at, and pathways that run through a cellular stress response are a well known category for non linear behaviour, where more exposure produces a plateau or a reversal rather than more effect. The cost rises linearly. The benefit is undocumented.

Storage Once the Vial Is Mixed

Lyophilised MOTS-c is stable for a long period in a freezer and for a shorter one in a fridge. Reconstituted, it belongs in the refrigerator and should be treated as having a working life measured in weeks rather than months. With bacteriostatic water, three to four weeks refrigerated is the usual working assumption, which lines up conveniently with the one to two weeks a 10mg vial lasts at common doses.

Freeze thaw cycling after reconstitution is the failure mode to avoid, along with heat exposure in transit and vigorous shaking. The storage guide covers the handling rules in detail. The practical point for dosing is that a degraded vial does not announce itself. A protocol that stops working after week three is at least as likely to be a storage problem as a tolerance problem.

Where MOTS-c Dosing Sits Against Its Neighbours

For context, most metabolic peptides people compare MOTS-c to run on completely different scales. SS-31 is dosed in similar milligram territory. 5-Amino-1MQ is usually oral and dosed in the 50mg to 150mg range. Epithalon runs short intensive blocks at 5mg to 10mg daily rather than weekly. The scales are not comparable and a dose figure borrowed from one does not inform another.

Within a longevity oriented protocol, MOTS-c is usually one component rather than the whole thing, and the longevity category page covers how the pieces are normally combined. Vendor selection is covered in the AminoClub review and the Pantheon review for the two sources linked above.

Key Takeaways

• Circulating protocols cluster at 5mg to 10mg weekly, most commonly 2.5mg to 3.5mg three times a week
• No human dose finding study exists, so every figure here is a market convention rather than a derived dose
• Mouse doses were weight scaled and do not translate to a human number by naive multiplication
• Reconstituting a 10mg vial with 2mL gives 5mg/mL, putting 2.5mg at 25 units on a U-100 syringe
• Three times weekly is better supported by the mechanism than daily dosing, which mostly adds injections
• Four to eight week blocks with a break are the conservative structure for a compound that mimics an energy stress signal
• Pre training timing is a reasonable guess but consistency of dosing matters considerably more
• Above roughly 10mg weekly there is no documented additional benefit and the cost rises linearly

Frequently Asked Questions

What is the usual MOTS-c dosage?

Protocols in circulation cluster at 5mg to 10mg per week in total, most often delivered as three injections of roughly 2.5mg to 3.5mg on non consecutive days. A 10mg vial therefore covers one to two weeks depending on where in that range a protocol sits. These are market conventions rather than trial derived doses, because no human dose finding study for MOTS-c has been published.

How do you reconstitute a 10mg MOTS-c vial?

Adding 2mL of bacteriostatic water to a 10mg vial gives 5mg per mL, which means 5mg sits at 50 units on a standard U-100 insulin syringe and a 2.5mg dose is 25 units. Adding 1mL instead doubles the concentration to 10mg per mL, so 2.5mg becomes 12.5 units, which is harder to read accurately. Two millilitres is the more forgiving choice for anyone splitting doses.

Should MOTS-c be injected daily or three times a week?

Three times weekly is the more common pattern and the more defensible one. MOTS-c acts through AMPK signalling and downstream transcriptional changes rather than through sustained receptor occupancy, so the biological effect outlasts the plasma presence of the peptide. Daily low dose splits exist but multiply injections and cost without a documented advantage.

How long should a MOTS-c cycle run?

Four to eight weeks is the usual block, followed by a break of similar length. The reasoning is precautionary rather than evidence based: MOTS-c works partly by mimicking an energy stress signal, and no long term human exposure data exists to say what continuous signalling does. Longer blocks are common in practice and are not supported by anything published.

Does MOTS-c need to be timed around training?

The common practice is to inject on training days, roughly thirty to sixty minutes before a session, on the logic that MOTS-c and exercise both converge on AMPK. That logic is reasonable but untested in humans, and the transcriptional effects it triggers unfold over hours rather than minutes. Consistency of dosing matters considerably more than the timing window.

Is a higher MOTS-c dose more effective?

There is no dose response curve in humans to answer that from, and the mouse studies used weight scaled doses that do not translate cleanly. Signalling peptides that work through a stress response pathway frequently show a plateau or a reversal at higher exposure rather than a straight line of benefit. Running above the common range increases cost and unknowns without a documented return.